PDGFRB and neoplasm: Anlotinib is a novel, oral, small‐molecule TKI, that antagonizes multiple tumor proangiogenic and proliferative signaling pathways.22 Its prime targets include VEGFR 1 to 3, FGFR 1 to 4, PDGFR α, β, and c‐Kit (Figure 7).